Your Premier Source for Cannabis Insights and Trends

How Psychedelic VCs do Due Diligence on Potential Investments – Sam Tabone, Empath Ventures



🍄 Today’s guest is Samantha Tabone. Sam is a Partner at Empath Ventures where she leads in-depth technical and scientific due diligence on Empath’s psychedelic biotech investments. In this episode, Sam breaks down the due diligence process that Empath uses when evaluating potential investments in psychedelic biotech companies. We go deep in this one, and spend almost 2 hours getting into the details of analyzing Team, Intellectual Property, Scientific Foundations and Strategy.

Prior to Empath, Sam served as the VP of R&D for PurMinds, a neuromedicine startup developing novel therapeutics for neurodegenerative diseases. As an independent consultant she’s led projects for leading psychedelic companies including Beckley Psytech, advised family offices on Life Science investment strategies, and worked as a temporary strategic director at several biotech startups.

Sam has been fascinated with neuroscience and psychedelics (especially DMT) since she was in her teens. She’s most excited about funding psychedelic startups working towards solutions for complex neurological disorders.

She holds a B.S. in Chemistry from the University of Toronto and attended the University of Wisconsin-Madison’s Pharmaceutical Sciences Master’s program.

🔗 Connect with Sam on LinkedIn: https://www.linkedin.com/in/samanthatabone/

🐦 Follow Brom on Twitter: https://www.twitter.com/therealbrom

🍄 Empath Ventures: https://www.empath.vc

Make sure to subscribe to the show!

⏰ Timestamps:

0:00 Who is Samantha Tabone?
6:05 Generalists vs Specialists?
8:14 How has not getting a PhD impacted Sam’s career?
16:25 High level steps of deal execution.
19:19 A sneak peak into Sam’s due diligence framework.
21:43 How a data room’s organization can reflect a company’s work ethic/structure.
24:26: Data room must-haves.
27:28 Breaking-down the due diligence process: The Team.
28:43 The Team: Contract status-checks, term lengths, and expected milestones.
31:01 The Team: Condition checks in employment contracts.
32:16 The Team: Are advisors on multiple advisory boards a red flag?
34:00 The Team: Foreign industry founders/CEOs – the importance of intention and learning capabilities.
40:40 The Team: Red flags in resumes – hype wave riders.
41:25 The Team: Should founders in the psychedelics space have a long personal history with psychedelics?
46:01 The Team: Ex-academic turned founder – good thing, bad thing, or depends on the situation?
48:23 Intellectual Property: Overview
50:04 Intellectual Property: What is in-licensing?
52:17 Intellectual Property: Are simple tweaks to existing molecules not ambitious enough?
57:00 Intellectual Property: IP filing process and IP wars.
58:49 Intellectual Property: Different types of patents.
1:04:23 Intellectual Property: Will abuse-resistant delivery mechanisms be critical for psychedelic prescriptions?
1:06:16 Intellectual Property: Missing information in data rooms.
1:10:23 Intellectual Property: Tanimoto Matrix — comparing and contrasting molecules.
1:14:52: AI – Evaluating computational tools
1:18:53 What is multi-omics data ?
1:23:34 Scientific Foundations: Overview
1:27:56 Scientific Foundations: An overview of animal models.
1:30:22 Scientific Foundations: Do animal models translate to humans?
1:33:35 Scientific Foundations: Novel approaches to drug delivery programs.
1:34:46 Product Development, Strategy, Operations: How important is having a plan?
1:39:21 Product Development, Strategy, Operations: The importance of documentation.
1:41:30 Product Development, Strategy, Operations: Go vs No-Go decision determinants.
1:44:52 Product Development, Strategy, Operations: Bad strategy can kill a program.
1:46:02 Product Development, Strategy, Operations: The importance of CRO supervision.
1:54:40 Final thoughts – the philosophy of due diligence

source

Comments are closed.